Summary
The relative bioavailability and diuretic effect of 2 commercially available tablet preparations of furosemide 40 mg was examined in 10 healthy male volunteers. A close linear relationship between the urinary excretion rate of furosemide and the rate of sodium ion excretion in urine and/or flow rate of urine was demonstrated. There were no significant differences in the urinary excretion of furosemide, sodium and potassium ions or urinary volume following the oral doses. The difference in drug content affected the urinary recovery of furosemide over 24 h but had no effect on the pharmacological response. The analytical power of ANOVA using the various parameters of the responses to furosemide was no lower than when the parameters of urinary excretion of furosemide were used.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beermann B, Groschinsky-Grind M (1980) Clinical pharmacokinetics of diuretics. Clin Pharmacokinet 5: 221–245
Benet LZ (1979) Pharmacokinetics/pharmacodynamics of furosemide in man: A review. J Pharmacokinet Biopharm 7: 1–27
Culter RE, Blair AD (1979) Clinical pharmacokinetics of frusemide. Clin Pharmacokinet 4: 279–296
Unno M, Tomino A, Yamasaki S (1977) Pharmaceutical studies on furosemide tablets. Abstracts of Papers, the 97th Annual Meeting of Pharmaceutical Society of Japan, Tokyo, pp 253
Beermann B, Dalen E, Lindstrom B (1978) Bioavailability of two frusemide preparations. Br J Clin Pharmacol 6: 537–538
Paton DM (1980) Bioavailability of two preparations of frusemide. NZ Med J 91: 208–210
Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: Clinical application of pharmacokineticpharmacodynamic models. Clin Pharmacokinet 6: 429–453
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications Inc., Hamilton, Illinois, pp 307–336
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications Inc., Hamilton, Illinois, pp 285–306
Bailey DE (1971) Probability and statistics: Models for research. John Wiley & Sons Inc., New York
Heck HA, Buttrill Jr SE, Flynn NW, Dyer RL, Anbar M, Cairns T, Dighe S, Cabana BE (1979) Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: Increasing the power of bioavailability tests. J Pharmacokinet Biopharm 7: 233–248
Branch RA, Roberts CJC, Homeida M, Levine D (1977) Determination of response to frusemide in normal subjects. Br J clin Pharmacol 4: 121–127
Fuller R, Hoppel C, Ingalls ST (1981) Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clin Pharmacol Ther 30: 461–467
Andreasen F, Pedersen OL, Mikkelsen E (1978) Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension. Eur J Clin Pharmacol 14: 237–244
Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P (1981) Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 20: 27–33
Smith DE, Gee WL, Brater DC, Lin ET, Benet LZ (1980) Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharm Sci 69: 571–575
Stason WB, Cannon PJ, Heinemann HO, Laragh JH (1966) Furosmide, a clinical evaluation of its diuretic action. Circulation 34: 910–920
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ogata, H., Zugarni, S., Ejima, A. et al. Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers. Eur J Clin Pharmacol 24, 791–796 (1983). https://doi.org/10.1007/BF00607089
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607089